BDI Visits US Ellison Cancer Drug Production Facility... "Confirming Key Issues"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 6th that it visited the production facility of its U.S. subsidiary, Ellison Pharmaceuticals (Ellison), to check the progress of clinical trials and key issues related to its major pipelines.

VIDI recently met with the newly recruited Medical Officer at Ellison to receive reports on clinical preparation status, current progress, and future plans. They also visited the production facility of the pancreatic cancer second-line treatment drug, Glufosfamide, located in Maryland, together with Edwin Thomas, CEO of Ellison.

In addition, VIDI confirmed that the Phase 3 clinical trial of Glufosfamide for pancreatic cancer is progressing smoothly with 480 patients enrolled to date. Furthermore, discussions were held with Ellison regarding the possibility of conducting additional clinical trials in Korea and ways to significantly reduce development costs and timelines.

Based on the matters confirmed and discussed during this visit, VIDI plans to visit the U.S. again at the end of this year. At that time, VIDI intends to meet sequentially with companies related to the development of major pipelines alongside Ellison to make every effort to achieve faster clinical results.

A VIDI official stated, “Ellison aims to obtain FDA approval for Glufosfamide in early 2023 and to begin pharmaceutical sales within 2023,” adding, “VIDI will spare no effort to provide the best support in cooperation with Ellison to ensure commercialization within the targeted timeframe.”

He continued, “VIDI maintains close communication with Ellison through U.S. visits and regular video meetings,” and added, “In addition to Glufosfamide, we will provide maximum support to ensure the rapid commercialization of Ellison’s other pipelines as well.”